Capecitabine and Temozolomide for Neuroendocrine Cancers

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

December 31, 2013

Study Completion Date

October 31, 2014

Conditions
Neuroendocrine Tumors
Interventions
DRUG

Capecitabine

"Capecitabine 1500 mg/m2/day (PO divided BID) with a maximum daily dose of 2500mg Two week treatment regimen followed by two weeks off treatment, repeated for 12 cycles~After patients have completed 12 cycles with no signs of progression of disease, radiologic evaluation (CT or MRI) will be done after three cycles. This will result in two 28 day cycles and one 35 day cycle."

DRUG

Temozolomide

"Temozolomide 150-200 mg/m2/day (PO divided BID).~Two week treatment regimen followed by two weeks off treatment, repeated for 12 cycles~After patients have completed 12 cycles with no signs of progression of disease, radiologic evaluation (CT or MRI) will be done after three cycles. This will result in two 28 day cycles and one 35 day cycle."

Trial Locations (1)

10032

Columbia University Medical Center, New York

All Listed Sponsors
lead

Columbia University

OTHER

NCT00869050 - Capecitabine and Temozolomide for Neuroendocrine Cancers | Biotech Hunter | Biotech Hunter